RQ Biotechnology Ltd. Celebrates Milestone with Grant of GB Patent Covering its Licensed Clinical-Stage Antibody for the Prevention and Treatment of COVID-19

March 18, 2024
  • The issued patent covers sipavibart, the monoclonal antibody currently in AstraZeneca’s SUPERNOVA Phase I/III clinical trial for the prevention of COVID-19.
  • Further patents are pending in other countries with favourable outcomes anticipated.

RQ Biotechnology Ltd. (“RQ”) a leader in the discovery of antibodies for the treatment of infectious disease, today announced that the UK Intellectual Property Office (IPO) has granted its patent application covering the company’s monoclonal antibody, which is exclusively licensed to AstraZeneca, for the prevention and treatment of COVID-19.

The patent (GB2614651) is RQ’s first issued patent and progressed rapidly to grant just over two years from the discovery of the monoclonal antibody that it covers. The patent is part of RQ’s portfolio that includes over 23 patent applications in numerous countries including the US, EU, Japan and China. RQ anticipates favourable outcomes in other countries will follow on from GB2614651.

Mike Westby, CEO of RQ commented: “We are delighted by the fast progression of this patent application to grant, a further testament to RQ’s commitment to rapid impact for vulnerable patients in areas of current unmet medical and public health need. This achievement follows the entry of our first monoclonal antibody into clinical testing only 12 months after discovery. We are looking forward to making additional patent applications as our active discovery programmes begin to bear fruit”.

Notes to Editors

RQ Bio’s mission is to develop medicines based on potent broad-spectrum mAbs to provide instant immunity and protect vulnerable people from life threatening viral diseases. RQ Bio has achieved this by combining innovative excellence in core areas to create a smarter approach to antibody generation. RQ Bio has multiple sources of leads and a deep collaboration with the University of Oxford. RQ Bio was founded by scientific experts previously involved with the UK BIA Antibody Taskforce, which worked to build a community of infectious disease antibody experts focussed on the development of rapid and efficient delivery of highly potent neutralising antibodies to help support the UK COVID-19 response.